Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Current Assets (2023 - 2025)

CG Oncology's Current Assets history spans 3 years, with the latest figure at $759.5 million for Q4 2025.

  • For Q4 2025, Current Assets rose 0.7% year-over-year to $759.5 million; the TTM value through Dec 2025 reached $759.5 million, up 0.7%, while the annual FY2025 figure was $759.5 million, 0.7% up from the prior year.
  • Current Assets reached $759.5 million in Q4 2025 per CGON's latest filing, up from $695.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $759.5 million in Q4 2025 to a low of $194.1 million in Q4 2023.
  • Average Current Assets over 3 years is $608.0 million, with a median of $673.0 million recorded in 2025.
  • Peak YoY movement for Current Assets: surged 288.52% in 2024, then rose 0.7% in 2025.
  • A 3-year view of Current Assets shows it stood at $194.1 million in 2023, then soared by 288.52% to $754.2 million in 2024, then rose by 0.7% to $759.5 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Current Assets are $759.5 million (Q4 2025), $695.8 million (Q3 2025), and $673.0 million (Q2 2025).